An in vitro study, which computationally predicted new TKI therapy-induced BCR-ABL neoantigens, could demonstrate specific CD8+ T cells against a HLA-A*03-restricted peptide in the blood of two CML patients [149]. The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.